The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).
 
Sangeetha Venugopal
No Relationships to Disclose
 
Courtney Denton Dinardo
Leadership - Notable Labs
Stock and Other Ownership Interests - Notable Labs
Honoraria - Abbvie; Agios; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Takeda
Consulting or Advisory Role - Abbvie; Agios; Celgene
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo
 
Koichi Takahashi
Honoraria - Celgene; DAVA Pharmaceuticals; GlaxoSmithKline; Novartis; SymBio Pharmaceuticals
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Novartis; SymBio Pharmaceuticals
Research Funding - Onconova Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; DAVA Pharmaceuticals; GlaxoSmithKline; SymBio Pharmaceuticals
 
Marina Konopleva
Honoraria - Abbvie; Amgen; Amgen; Genentech; KisoJi Biotechnology; Roche; Stemline Therapeutics
Consulting or Advisory Role - AbbVie; Amgen; Forty Seven; Genentech/Roche; Janssen; KisoJi Biotechnology; KisoJi Biotechnology; Roche; Stemline Therapeutics
Research Funding - Abbvie (Inst); Ablynx (Inst); Agios (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Roche (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Eli LIlly- Research Funding; Issued/ Licensed; Novartis- PENDING; Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities); Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities)
 
Sanam Loghavi
Stock and Other Ownership Interests - Abbvie; PureTech
Honoraria - Curio Science
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Global; Seagen
Travel, Accommodations, Expenses - Curio Science
 
Gautam Borthakur
Consulting or Advisory Role - Argenx; BiolineRx; BioTheryX; Catamaran Bio; Nkarta; Novartis; PTC Therapeutics; Takeda; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Nkarta (Inst); Nkarta (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); TCR2 Therapeutics (Inst); Treadwell Therapeutics (Inst); XBiotech (Inst)
 
Amy Elizabeth Dezern
Consulting or Advisory Role - Celgene; Gilead Sciences; Novartis
Research Funding - Astex Pharmaceuticals (Inst); celgene (Inst)
Travel, Accommodations, Expenses - Abbvie
 
Lucia Masarova
No Relationships to Disclose
 
Naval Guastad Daver
Honoraria - Abbvie; Astellas Pharma; BMS; Immunogen; Incyte; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Immunogen; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Novartis; Otsuka; Pfizer; SERVIER; Sunesis Pharmaceuticals; Syndax; Trillium Therapeutics
Research Funding - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Immunogen; Incyte; Karyopharm Therapeutics; Nohla Therapeutics; Novartis; Pfizer; Servier; SOBI; Sunesis Pharmaceuticals
 
Nicholas James Short
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca
Research Funding - Astellas Pharma; Takeda
 
Yesid Alvarado
Research Funding - Astex Pharmaceuticals (Inst); BerGenBio (Inst); Daiichi Sankyo/Lilly (Inst); FibroGen (Inst); Jazz Pharmaceuticals (Inst); Sun Pharma (Inst)
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Orsenix; Pfizer; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Orsenix; Syros Pharmaceuticals; Taiho Oncology; Taiho Oncology
Research Funding - Amgen; Bristol-Myers Squibb; Cellerant; Macrogenics; Selvita; Xencor
 
Guillermo Montalban-Bravo
No Relationships to Disclose
 
Koji Sasaki
Honoraria - Otsuka
Consulting or Advisory Role - Novartis; Pfizer; Takeda
Research Funding - Novartis
Travel, Accommodations, Expenses - Otsuka
 
Ricardo Delumpa
No Relationships to Disclose
 
Mikkael A. Sekeres
Consulting or Advisory Role - Celgene; Millennium; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Takeda (Inst)
 
Bhumika J Patel
Speakers' Bureau - Alexion Pharmaceuticals; Apellis Pharmaceuticals
 
Gail J. Roboz
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; Amphivena; argenx; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Celgene; Celltrion; Daiichi Sankyo; Eisai; Genentech/Roche; Genoptix; GlaxoSmithKline; Helsinn Therapeutics; Janssen; Jazz Pharmaceuticals; MedImmune; MEI Pharma; Mesoblast; Novartis; Orsenix; Otsuka; Pfizer; Roche; Sandoz; Takeda; Trovagene
Research Funding - Abbvie (Inst); Agios (Inst); amphivena (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); Cellectis (Inst); CTI (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Agios; Amgen; Amphivena; Array BioPharma; Astex Pharmaceuticals; Bayer; Celgene; Celltrion; Clovis Oncology; Eisai; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Roche/Genentech; Sandoz; Sunesis Pharmaceuticals
 
Hagop M. Kantarjian
Honoraria - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; ARIAD; Bristol-Myers Squibb; Immunogen; Orsenix; Pfizer; Takeda
Research Funding - Abbvie (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst)
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Celgene; Helsinn Healthcare
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb; Celgene; Helsinn Therapeutics; Jazz Pharmaceuticals
Research Funding - Abbvie; Amphivena; Astex Pharmaceuticals; Bristol-Myers Squibb; celgene; H3 Biomedicine; Helsinn Therapeutics; Merck; Novartis; Onconova Therapeutics